Boulder, Colorado - July 16, 2007 - Bolder BioTechnology, Inc. today announced that it has been awarded a $762,475 Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health. The grant supports research to improve the pharmacological properties of a human protein, gamma interferon, to enhance its ability to stimulate the body's immune system to fight infections. Joe Cox, Ph.D., Principal Investigator for the grant commented "We are delighted to receive continued support from NIAID for our second generation gamma interferon program. With funds provided by a Phase I SBIR grant award from NIAID we demonstrated the feasibility of preparing a gamma interferon analog that has an extended duration of action in vivo. Importantly, we found that the longer-acting gamma interferon analog was significantly more effective than gamma interferon in an animal disease model. This new grant award will allow us to perform additional preclinical efficacy studies and optimize the manufacturing process for this protein, which are required before testing the protein in human clinical trials. Gamma interferon is an approved therapy for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Our second generation gamma interferon analog may offer patients a more convenient and potentially more effective therapy for their disease. The protein also may prove useful for treating fungal and viral infections and various cancers. "
The SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs. Bolder BioTechnology previously received a $100,000 Phase I SBIR grant award from NIAID to demonstrate the feasibility of producing long-acting gamma interferon analogs.
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site atwww.bolderbio.com.
Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.
Contact information: Joe Cox, Ph.D., President (303) 420-4420 ext.202